{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:17Z","timestamp":1793146637642,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>GSK2838232 is a second-generation, potent, small-molecule, oral human immunodeficiency virus type 1 (HIV-1) maturation inhibitor for once-daily administration boosted with a pharmacoenhancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The phase 2a, proof-of-concept study was an open-label, adaptive dose-ranging design. Safety, pharmacokinetics, and efficacy of GSK2838232 boosted by cobicistat were evaluated in individuals with HIV-1 infection. The study participants (N = 33) received GSK2838232 once daily across a range of doses (20\u2013200 mg) with cobicistat 150 mg for 10 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>GSK2838232 was safe and well tolerated with no clinically meaningful changes in safety parameters or adverse events. Exposure (maximum concentration and area under the concentration-time curve from time zero to the concentration at 24 hours postdose) increased 2- to 3-fold with repeated dosing in an approximately dose-proportional manner, reaching steady-state by day 8 with a half-life (t\u00bd) from 16.3 to 19.2 hours. Clearance and t\u00bd values were not dependent on dose. Viral load declined from baseline with all GSK2838232 doses. Mean maximum declines from baseline to day 11 in HIV-1 RNA log10 copies\/mL with the 20-mg, 50-mg, 100-mg, and 200-mg cohorts were \u22120.67, \u22121.56, \u22121.32, and \u22121.70, respectively. CD4+ cell counts increased at doses \u226550 mg.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>GSK2838232 with cobicistat was well tolerated and exhibited efficacy as a short-term monotherapy in participants with HIV-1. This positive proof-of-concept study supports the continued development of GSK2838232 for the treatment of HIV as part of combination antiretroviral therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03045861.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz938","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T19:27:47Z","timestamp":1570130867000},"page":"1255-1262","source":"Crossref","is-referenced-by-count":29,"title":["A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection"],"prefix":"10.1093","volume":"71","author":[{"given":"Edwin","family":"DeJesus","sequence":"first","affiliation":[{"name":"Orlando Immunology Center, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Harward","sequence":"additional","affiliation":[{"name":"Clinical Development, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxanne C","family":"Jewell","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Johnson","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Dumont","sequence":"additional","affiliation":[{"name":"Clinical Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Wilches","sequence":"additional","affiliation":[{"name":"Clinical Development, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Halliday","sequence":"additional","affiliation":[{"name":"Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Stockley Park, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L","family":"Talarico","sequence":"additional","affiliation":[{"name":"Clinical Virology, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gan","sequence":"additional","affiliation":[{"name":"Biostatistics, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Global Clinical Sciences and Delivery, GlaxoSmithKline, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[{"name":"Bakersfield Family Medical Center, Bakersfield, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Scribner","sequence":"additional","affiliation":[{"name":"Diagnostic Clinic of Longview, Center for Clinical Research, Longview, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moti","family":"Ramgopal","sequence":"additional","affiliation":[{"name":"Midway Immunology and Research Center, Fort Pierce, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Benson","sequence":"additional","affiliation":[{"name":"Well Medical Center, Berkeley, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A","family":"Johns","sequence":"additional","affiliation":[{"name":"Human Immunodeficiency Virus Discovery Performance Unit, GlaxoSmithKline, Research Triangle Park, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"key":"2020082200571945700_CIT0001","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/1389557511209030236","article-title":"Targeting strategies for human immunodeficiency virus: a combinatorial approach","volume":"12","author":"Saxena","year":"2012","journal-title":"Mini Rev Med Chem"},{"key":"2020082200571945700_CIT0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/med.20138","article-title":"HIV entry inhibitors and their potential in HIV therapy","volume":"29","author":"Qian","year":"2009","journal-title":"Med Res Rev"},{"key":"2020082200571945700_CIT0003","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/QAD.0b013e328331c83b","article-title":"Can the further clinical development of bevirimat be justified?","volume":"24","author":"Wainberg","year":"2010","journal-title":"AIDS"},{"key":"2020082200571945700_CIT0004","article-title":"BMS-955176: characterization of a second-generation HIV-1 maturation inhibitor","author":"Nowicka-Sans"},{"key":"2020082200571945700_CIT0005","author":"Collins"},{"key":"2020082200571945700_CIT0006","article-title":"GSK2838232, a second generation HIV-1 maturation inhibitor with an optimized virology profile","author":"Jeffrey"},{"key":"2020082200571945700_CIT0007","doi-asserted-by":"crossref","first-page":"e00408","DOI":"10.1002\/prp2.408","article-title":"The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects","volume":"6","author":"Johnson","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"2020082200571945700_CIT0008","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/jac\/dkw032","article-title":"Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications","volume":"71","author":"Marzolini","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020082200571945700_CIT0009","first-page":"132","article-title":"2017 Update of the drug resistance mutations in HIV-1","volume":"24","author":"Wensing","year":"2017","journal-title":"Top Antivir Med"},{"key":"2020082200571945700_CIT0010","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/cid\/cix239","article-title":"Antiviral activity, safety, and exposure-response relationships of GSK3532795, a second-generation human immunodeficiency virus type 1 maturation inhibitor, administered as monotherapy or in combination with atazanavir with or without ritonavir in a phase 2a randomized, dose-ranging, controlled trial (AI468002)","volume":"65","author":"Hwang","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz938\/31141119\/ciz938.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1255\/33672010\/ciz938.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1255\/33672010\/ciz938.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T04:57:45Z","timestamp":1598072265000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/5\/1255\/5643945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,11,26]]},"published-print":{"date-parts":[[2020,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz938","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2019,11,26]]}}}